AR126566A1 - METHODS FOR THE TREATMENT AGAINST CANCER WITH 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-IL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-IL-1,3 ,5-TRIAZIN-2-IL)PHENYL]UREA - Google Patents
METHODS FOR THE TREATMENT AGAINST CANCER WITH 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-IL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-IL-1,3 ,5-TRIAZIN-2-IL)PHENYL]UREAInfo
- Publication number
- AR126566A1 AR126566A1 ARP220101971A ARP220101971A AR126566A1 AR 126566 A1 AR126566 A1 AR 126566A1 AR P220101971 A ARP220101971 A AR P220101971A AR P220101971 A ARP220101971 A AR P220101971A AR 126566 A1 AR126566 A1 AR 126566A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- week
- period
- methods
- administration
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 abstract 3
- 229950008209 gedatolisib Drugs 0.000 abstract 3
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos para tratar el cáncer en un sujeto humano. El método incluye seleccionar un sujeto que necesita tratamiento contra el cáncer; administrar al sujeto una cantidad terapéuticamente eficaz de gedatolisib al menos una vez por semana durante un período de tres semanas; discontinuar la administración de gedatolisib por un período de una semana; y reanudar la administración de gedatolisib al menos una vez por semana después del período de discontinuación. La administración durante al menos un período de tres semanas y la administración discontinuada durante al menos un período de una semana constituye un ciclo, donde el ciclo se repite durante al menos dos ciclos.Methods for treating cancer in a human subject. The method includes selecting a subject in need of cancer treatment; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinue administration of gedatolisib for a period of one week; and resume gedatolisib administration at least once a week after the discontinuation period. Administration for at least a three-week period and discontinued administration for at least a one-week period constitutes a cycle, where the cycle is repeated for at least two cycles.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063285327P | 2020-12-01 | 2020-12-01 | |
| US202163225707P | 2021-07-26 | 2021-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126566A1 true AR126566A1 (en) | 2023-10-25 |
Family
ID=88679228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101971A AR126566A1 (en) | 2020-12-01 | 2022-07-25 | METHODS FOR THE TREATMENT AGAINST CANCER WITH 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-IL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-IL-1,3 ,5-TRIAZIN-2-IL)PHENYL]UREA |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126566A1 (en) |
-
2022
- 2022-07-25 AR ARP220101971A patent/AR126566A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005812A (en) | METHODS OF TREATMENT OF DISEASES AND DISORDERS RELATED TO LYSINE-SPECIFIC DEMETHYLASE 1 WITH LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITORS. | |
| JOP20200156A1 (en) | Esketamine for the treatment of depression | |
| MX2022013410A (en) | Methods of treatment. | |
| MX2017005875A (en) | Methods for treating ocular diseases. | |
| AR055038A1 (en) | METHOD AND COMPOUND TO TREAT PERIPHERAL VASCULAR DISEASES | |
| CO6220969A2 (en) | WEEKLY ADMINSITRATION OF DIPEPTIDILO PEPTIDASE INHIBITORS | |
| CO2020000939A2 (en) | Dihydroergotamine Nasal Dosage Forms | |
| MX2015005879A (en) | Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid. | |
| RU2019100037A (en) | METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS USING LSD1 INHIBITOR | |
| AR120399A1 (en) | A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER | |
| MX2023007080A (en) | Method for treating fibrosis. | |
| CL2024003601A1 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases. | |
| AR052565A1 (en) | PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS | |
| CO2022015018A2 (en) | Methods and means to modify hemodynamics in infections | |
| CL2022001102A1 (en) | Methods for the treatment of depressive disorders. | |
| AR126566A1 (en) | METHODS FOR THE TREATMENT AGAINST CANCER WITH 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-IL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-IL-1,3 ,5-TRIAZIN-2-IL)PHENYL]UREA | |
| CL2024000208A1 (en) | Gedatolisib and its combinations for use in the treatment of cancer | |
| AR122595A1 (en) | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| MX2023013514A (en) | METHODS FOR TREATING INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME. | |
| MX2022006803A (en) | Ophthalmic formulations for the treatment of presbyopia. | |
| MX2024015758A (en) | Methods of treating glioblastoma with prodrugs of riluzole | |
| AR105087A1 (en) | METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT | |
| MX2025011488A (en) | Dosing regiment of azd5305 | |
| MX2020006429A (en) | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING AN FP AGONIST AND A BETA BLOCKER. |